Filing identity and reporting period
Important identity mismatch: The supplied filing is AVROBIO, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2023, not a filing for Tectonic Therapeutic, Inc. This summary reflects AVROBIO’s filing.
AVROBIO was a gene therapy company focused on rare diseases. On July 12, 2023, it halted development of its programs and began exploring strategic alternatives to maximize stockholder value. It had no product revenue.
Financial results and liquidity
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $14.8 million | $15.9 million | $43.3 million | $54.0 million |
| General and administrative expense | $6.3 million | $7.1 million | $18.7 million | $26.1 million |
| Net income (loss) | $(21.6) million | $(23.0) million | $20.9 million | $(80.9) million |
| Operating cash flow | Not provided separately | Not provided separately | $(55.2) million | $(73.5) million |
Margins are not meaningful because the company had no revenue. Nine-month 2023 net income includes an $83.7 million gain, net of transaction costs, from selling its cystinosis program to Novartis; it does not indicate recurring profitability. Q3 included a $1.8 million impairment loss.
At September 30, 2023, cash and cash equivalents were $105.8 million, restricted cash was $0.7 million, total current assets were $109.2 million, and current liabilities were $7.6 million. Total assets were $110.5 million and stockholders’ equity was $102.9 million. The $15.0 million term loan, together with interest and other charges, was repaid in full and terminated in June 2023; no note payable remained at quarter-end. Operating lease liabilities totaled $1.8 million.
Nine-month cash flow included $84.9 million provided by investing activities, chiefly the $83.7 million net proceeds from the asset sale, and $16.1 million used in financing activities, chiefly debt repayment. Cash, cash equivalents and restricted cash rose by $13.7 million to $106.5 million over the period.
Material changes and management commentary
- Compared with the prior-year nine-month period, operating expenses fell $18.1 million, including reductions of $10.7 million in R&D and $7.4 million in G&A, principally reflecting lower personnel, consulting and manufacturing costs.
- The company sold its cystinosis gene therapy program and related assets to Novartis for $87.5 million cash, completed June 9, 2023. It used proceeds to repay its term loan.
- Following the development halt, AVROBIO terminated Company-sponsored Gaucher treatment and long-term follow-up studies, discontinued its Hunter program, and terminated its University of Manchester license and research agreement. It reported three remaining candidates—Gaucher, Pompe and Fabry—none in active clinical development. The Fabry license termination was scheduled to take effect January 4, 2024.
- The July 2023 workforce reduction eliminated approximately 50% of employees. The company recorded $3.7 million of restructuring expense in the first nine months, with no related accrued payments remaining at September 30. A further 11 employees were terminated effective October 31; estimated severance and related costs were approximately $1.2 million.
- Management stated that September 30 cash and cash equivalents were expected to fund current planned operations and capital requirements for at least 12 months from the filing date. Management also noted that future viability depends on raising additional capital if development resumes; funding may not be available on acceptable terms.
Outlook, risks and contingencies
The strategic review had no set completion timetable, and the board had not approved a definitive course of action. Potential outcomes included an acquisition, merger, business combination, divestiture or, if no transaction is completed, possible dissolution and liquidation. The company cautioned that a transaction may not occur or create value; liquidation distributions would depend on timing and reserves for obligations and contingencies.
AVROBIO withdrew its November 2022 shelf registration statement on November 3, 2023. It said it would not sell shares under the associated $50 million ATM facility until a new Form S-3 shelf is filed and declared effective. It reported no material pending or threatened litigation and no material legal proceedings during the period. The company said disclosure controls and procedures were effective at the reasonable-assurance level as of September 30, 2023.
Important facts for investors to verify
- Confirm that AVROBIO, rather than Tectonic Therapeutic, is the issuer relevant to the requested filing.
- Review subsequent disclosures for the outcome and timing of the strategic alternatives process, including any liquidation decision or stockholder distribution plan.
- Assess cash use, strategic-review and wind-down costs, severance obligations, lease commitments, and the company’s stated cash runway.
- Confirm the status of the withdrawn shelf registration, ATM availability, and any subsequent financing or transaction that could dilute shareholders.
- Verify the final accounting and any remaining obligations associated with the Novartis asset sale, terminated licenses, and discontinued development programs.